PF-3845

Modify Date: 2024-01-02 19:39:02

PF-3845 Structure
PF-3845 structure
 Common Name PF-3845
CAS Number 1196109-52-0 Molecular Weight 456.460
Density 1.3±0.1 g/cm3 Boiling Point 623.6±55.0 °C at 760 mmHg
Molecular Formula C24H23F3N4O2 Melting Point N/A
MSDS Chinese USA Flash Point 330.9±31.5 °C
Symbol GHS06
GHS06		 Signal Word Danger

 Use of PF-3845


PF-3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM); showing negligible activity against FAAH2.IC50 value: 0.23 uMTarget: FAAHPF-3845 selectively inhibits FAAH by carbamylating FAAH's serine nucleophile [1]. PF-3845 treated mice (10 mg/kg, i.p.) shows rapid and complete inactivation of FAAH in the brain, as judged by competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed probe fluorophosphonate (FP)-rhodamine. PF-3845 shows a long duration of action up to 24 hour. PF-3845-treated mice also shows dramatic (>10-fold) elevation in brain levels of AEA and other NAEs (N-pamitoyl ethanolamine [PEA] and N-oleoyl ethanolamine [OEA]). FAAH is AEA-degrading enzyme fatty acid amide hydrolase. PF-3845 (1–30 mg/kg, oral administration [p.o.]) causes a dose dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg (rats are analyzed at 4 hour post dosing with PF-3845). At higher doses (10 and 30 mg/kg), PF-3845 inhibits pain responses to an equivalent, if not greater, degree than the nonsteroidal anti-inflammatory drug naproxen (10mg/kg, p.o.) [1]. PF-3845 (10 mg/kg, i.p.) significantly reverses LPS-induced tactile allodynia, but doesn't modify paw withdrawal thresholds in the saline-injected paw [2].

 Names

Name N-pyridin-3-yl-4-[[3-[5-(trifluoromethyl)pyridin-2-yl]oxyphenyl]methyl]piperidine-1-carboxamide
Synonym More Synonyms

 PF-3845 Biological Activity

Description PF-3845 is a selective fatty acid amide hydrolase (FAAH) inhibitor (Ki = 0.23 μM); showing negligible activity against FAAH2.IC50 value: 0.23 uMTarget: FAAHPF-3845 selectively inhibits FAAH by carbamylating FAAH's serine nucleophile [1]. PF-3845 treated mice (10 mg/kg, i.p.) shows rapid and complete inactivation of FAAH in the brain, as judged by competitive activity-based protein profiling (ABPP) with the serine hydrolase-directed probe fluorophosphonate (FP)-rhodamine. PF-3845 shows a long duration of action up to 24 hour. PF-3845-treated mice also shows dramatic (>10-fold) elevation in brain levels of AEA and other NAEs (N-pamitoyl ethanolamine [PEA] and N-oleoyl ethanolamine [OEA]). FAAH is AEA-degrading enzyme fatty acid amide hydrolase. PF-3845 (1–30 mg/kg, oral administration [p.o.]) causes a dose dependent inhibition of mechanical allodynia with a minimum effective dose (MED) of 3 mg/kg (rats are analyzed at 4 hour post dosing with PF-3845). At higher doses (10 and 30 mg/kg), PF-3845 inhibits pain responses to an equivalent, if not greater, degree than the nonsteroidal anti-inflammatory drug naproxen (10mg/kg, p.o.) [1]. PF-3845 (10 mg/kg, i.p.) significantly reverses LPS-induced tactile allodynia, but doesn't modify paw withdrawal thresholds in the saline-injected paw [2].
Related Catalog
References

[1]. Ahn K, et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol. 2009 Apr 24;16(4):411-20.

[2]. Booker L, et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol, 2012, 165(8), 2485-2496.

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 623.6±55.0 °C at 760 mmHg
Molecular Formula C24H23F3N4O2
Molecular Weight 456.460
Flash Point 330.9±31.5 °C
Exact Mass 456.177307
PSA 67.35000
LogP 3.72
Appearance of Characters white to tan
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.595
Storage condition Store at +4°C
Water Solubility DMSO: ≥45mg/mL

 Safety Information

Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H301
Precautionary Statements P301 + P310
Hazard Codes T
Risk Phrases 25
Safety Phrases 45
RIDADR UN 2811 6.1 / PGIII

 Synonyms

,PF3845,PF 3845
4-(3-(5-(trifluoromethyl)pyridin-2-yloxy)benzyl)-N-(pyridin-3-yl)piperidine-1-carboxamide
PF 3845 hydrate
N-(3-Pyridinyl)-4-(3-{[5-(trifluoromethyl)-2-pyridinyl]oxy}benzyl)-1-piperidinecarboxamide
PF-3845
cc-145
1-Piperidinecarboxamide, N-3-pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-
PF3845
Top Suppliers:I want be here

Get all suppliers and price by the below link:

PF-3845 suppliers

Price: $73/10mM*1mLinDMSO

Reference only. check more PF-3845 price

Related Compounds: More...
PF-06471553
1808094-07-6
PF-05085727
1415637-72-7
PF-03463275
1173177-11-1
PF-06815189
2218484-75-2
PF-06869206
2227425-05-8
PF 945863
893556-85-9
PF-06952229
1801333-55-0
PF-04531083
1079400-07-9
PF-06726304 acetate
2080306-28-9
4-((Cyclohexylamino)methyl)benzoic acid hydrochloride
1158522-08-7
1-[(2,4-Dichlorophenyl)methyl]-N-(1,1-dimethylethyl)-2-methyl-1H-indole-3-methanamine
940364-43-2
2-Methoxy-6-(pyrazol-1-yl)-benzonitrile
134104-43-1
tert-Butyl (2-(hydroxymethyl)pyridin-4-yl)carbamate
2052294-37-6
1H-3-Benzazepin-7-ol, 8-chloro-2,3,4,5-tetrahydro-5-(3-iodophenyl)-3-methyl-, (S)-
131615-57-1
(4-Methyl-tetrahydro-furan-2-yl)-methanol
6906-52-1
N-(1-cyanocyclopentyl)-2-[4-(4-fluorobenzenesulfonyl)-1,4-diazepan-1-yl]acetamide
930439-75-1
4,5,6,7-Tetrahydrobenzo[d]isoxazole-3-carbaldehyde
1018584-77-4
1-Bromo-2-[(2-methoxyethoxy)methoxy]benzene
94236-22-3
(2E)-4-[(2-Formyl-4-hydroxyphenyl)amino]-4-oxo-2-butenoic acid
865543-39-1
Chemsrc provides PF-3845(CAS#:1196109-52-0) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of PF-3845 are included as well.>> amp version: PF-3845

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved